These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 19953930

  • 1. [Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease].
    Du ZD, Di Z, Du JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF.
    Zhonghua Yi Xue Za Zhi; 2009 Jul 14; 89(26):1841-3. PubMed ID: 19953930
    [Abstract] [Full Text] [Related]

  • 2. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 27; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 27; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 5. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
    Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
    J Pediatr; 2000 Aug 27; 137(2):172-6. PubMed ID: 10931407
    [Abstract] [Full Text] [Related]

  • 6. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
    Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
    Singapore Med J; 2006 Sep 27; 47(9):780-4. PubMed ID: 16924360
    [Abstract] [Full Text] [Related]

  • 7. The treatment of Kawasaki syndrome with intravenous gamma globulin.
    Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP.
    N Engl J Med; 1986 Aug 07; 315(6):341-7. PubMed ID: 2426590
    [Abstract] [Full Text] [Related]

  • 8. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
    Kashef S, Safari M, Amin R.
    Kaohsiung J Med Sci; 2005 Sep 07; 21(9):401-4. PubMed ID: 16248123
    [Abstract] [Full Text] [Related]

  • 9. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 07; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 07; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 11. Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000).
    Lee KY, Han JW, Lee HS, Hong JH, Hahn SH, Lee JS, Whang KT.
    Pediatr Infect Dis J; 2004 Jan 07; 23(1):52-5. PubMed ID: 14743047
    [Abstract] [Full Text] [Related]

  • 12. [How does the time of diagnosis affect the course of disease in children with kawasaki syndrome? A retrospective analysis at one center].
    Raith W, Gamillscheg A, Heinzl B, Nagel BH, Koestenberger M, Beitzke A.
    Klin Padiatr; 2009 Jan 07; 221(2):83-8. PubMed ID: 19263328
    [Abstract] [Full Text] [Related]

  • 13. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May 07; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 14. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 07; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 15. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug 07; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 16. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.
    Arj-ong S, Chotivitayatarakorn P, Lertsapcharoen P, Khongphatthanayothin A, Thisyakorn C.
    J Med Assoc Thai; 2003 Jun 07; 86 Suppl 2():S179-88. PubMed ID: 12929987
    [Abstract] [Full Text] [Related]

  • 17. Characteristics of Kawasaki disease in older children.
    Cai Z, Zuo R, Liu Y.
    Clin Pediatr (Phila); 2011 Oct 07; 50(10):952-6. PubMed ID: 21628347
    [Abstract] [Full Text] [Related]

  • 18. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 07; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug 07; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 20. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
    J Paediatr Child Health; 2004 Aug 07; 40(9-10):524-9. PubMed ID: 15367145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.